Should I buy or sell Intellia Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares. View NTLA analyst ratings or view top-rated stocks .

What is Intellia Therapeutics' stock price target for 2024?

13 brokerages have issued 12-month target prices for Intellia Therapeutics' stock. Their NTLA share price targets range from $29.00 to $107.00. On average, they expect the company's stock price to reach $67.00 in the next twelve months. This suggests a possible upside of 207.2% from the stock's current price. View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts .

How have NTLA shares performed in 2024?

Intellia Therapeutics' stock was trading at $30.49 on January 1st, 2024. Since then, NTLA shares have decreased by 28.5% and is now trading at $21.81. View the best growth stocks for 2024 here .

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NTLA earnings forecast .

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its earnings results on Thursday, February, 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. The business earned ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the company earned ($1.40) EPS.

What ETFs hold Intellia Therapeutics' stock?

ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) , Morningstar US Small Growth (MSGR) , ARK Genomic Revolution ETF (ARKG) , Global X Genomics & Biotechnology ETF (GNOM) , ARK Innovation ETF (ARKK) , iShares Genomics Immunology and Healthcare ETF (IDNA) , Horizon Kinetics Medical ETF (MEDX) and Franklin Genomic Advancements ETF (HELX) .

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com . John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT) , CRISPR Therapeutics (CRSP) , NVIDIA (NVDA) , Alibaba Group (BABA) , Block (SQ) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Intel (INTC) , Invitae (NVTA) and Cisco Systems (CSCO) .

When did Intellia Therapeutics IPO?

Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and Green Alpha Advisors LLC (0.01%). Insiders that own company stock include David Lebwohl , Eliana Clark , Glenn Goddard , James Basta, Jean Francois Formela , John F Crowley , John M Leonard, John M Leonard , Laura Sepp-Lorenzino and Muna Bhanji. View institutional ownership trends .

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free NTLA Stock Alerts

$21.81

-1.11 (-4.84%)

(As of 04/16/2024 ET)

Compare

Today's Range: $21.80
▼
$22.84
50-Day Range: $22.92
▼
$32.80
52-Week Range: $21.80
▼
$47.48

Volume: 1.23 million shs
Average Volume: 1.53 million shs
Market Capitalization: $2.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $67.00

Get Intellia Therapeutics alerts:

Intellia Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.69 Rating Score
Upside/Downside: 207.2% Upside
$67.00 Price Target
Short Interest: Bearish
15.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.96
Based on 4 Articles This Week
Insider Trading: Selling Shares
$75,778 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.58) to ($5.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

202nd out of 930 stocks

Diagnostic Substances Industry

4th out of 12 stocks

3.3

Analyst's Opinion

Consensus Rating
Intellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Intellia Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
15.43% of the outstanding shares of Intellia Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Intellia Therapeutics has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in Intellia Therapeutics has recently increased by 9.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Intellia Therapeutics does not currently pay a dividend.
Dividend Growth
Intellia Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intellia Therapeutics has received a 74.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for genetic diseases", and "Basic medical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Intellia Therapeutics is -0.67.

2.2

News and Social Media Coverage

News Sentiment
Intellia Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Intellia Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 27 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $75,778.00 in company stock.
Percentage Held by Insiders
Only 3.00% of the stock of Intellia Therapeutics is held by insiders.
Percentage Held by Institutions
88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.58) to ($5.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intellia Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intellia Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intellia Therapeutics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Intellia Therapeutics Stock (NASDAQ:NTLA)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NTLA Stock News Headlines

April 12, 2024 | fool.com

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.

April 9, 2024 | fool.com

Bull Market and Beyond: 3 Stocks Just Waiting to Soar

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

April 8, 2024 | americanbankingnews.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $67.00 Average Price Target from Analysts

March 28, 2024 | benzinga.com

Smart Money Is Betting Big In NTLA Options

March 28, 2024 | fool.com

Better Cathie Wood Stock: Moderna vs. Intellia

March 22, 2024 | marketwatch.com

Intellia Therapeutics Ends Co-Development Agreement With Regeneron

March 22, 2024 | msn.com

Intellia opts out of hemophilia pact with Regeneron

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 21, 2024 | investorplace.com

Hot Stocks: The 3 Best Opportunities for Investing in Biotech

March 21, 2024 | investorplace.com

3 Stocks That Could Be the Next Big Thing in Gene Editing

March 20, 2024 | investing.com

Intellia begins phase 3 trial for CRISPR therapy NTLA-2001

March 18, 2024 | globenewswire.com

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

March 9, 2024 | fool.com

Is Intellia Therapeutics Stock a Buy Now?

March 6, 2024 | fool.com

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

February 29, 2024 | seekingalpha.com

Intellia Therapeutics Is On The Move

February 29, 2024 | fool.com

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

February 27, 2024 | fool.com

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

February 26, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)

February 26, 2024 | markets.businessinsider.com

Hold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive Dynamics

February 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Health

February 25, 2024 | finance.yahoo.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

February 24, 2024 | realmoney.thestreet.com

Intellia Therapeutics just downgraded at Goldman Sachs, here's why

February 24, 2024 | msn.com

Goldman Sachs Downgrades Intellia Therapeutics (NTLA)

February 23, 2024 | markets.businessinsider.com

Strong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial Standing

February 23, 2024 | finance.yahoo.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript

February 23, 2024 | markets.businessinsider.com

Intellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical Milestones

See More Headlines

Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: N/A
Current Symbol: NASDAQ:NTLA
CUSIP: N/A
CIK: 1652130
Web: www.intelliatx.com
Phone: (857) 285-6200
Fax: N/A
Employees: 526
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $67.00
High Stock Price Target: $107.00
Low Stock Price Target: $29.00
Potential Upside/Downside: +195.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.69
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-481,190,000.00
Net Margins: -893.34%
Pretax Margin: -1,326.51%
Return on Equity: -43.91%
Return on Assets: -36.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.67
Quick Ratio: 8.67

Sales & Book Value

Annual Sales: $36.28 million
Price / Sales: 60.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.73 per share
Price / Book: 1.93

Miscellaneous

Outstanding Shares: 96,110,000
Free Float: 93,223,000
Market Cap: $2.18 billion
Optionable: Optionable
Beta: 1.77

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. John M. Leonard M.D. (Age 67)
President, CEO & Director
Comp: $1.06M
Mr. Glenn G. Goddard CPA (Age 53)
Executive VP, CFO & Treasurer
Comp: $630.91k
Dr. Laura Sepp-Lorenzino Ph.D. (Age 63)
Executive VP & Chief Scientific Officer
Comp: $670.58k
Mr. James E. Basta Esq. (Age 58)
J.D., Executive VP, General Counsel & Corporate Secretary
Comp: $616.15k
Dr. David Lebwohl M.D. (Age 69)
Executive VP & Chief Medical Officer
Comp: $671.42k
Mr. Derek Hicks (Age 50)
Executive VP & Chief Business Officer
Comp: $823.42k
Mr. Nessan Bermingham Ph.D. (Age 51)
Founder & Member of Scientific Advisor Board
Comp: $1.38M
Dr. Rachel E. Haurwitz Ph.D. (Age 38)
Co-Founder
Dr. Andrew May Ph.D.
Founder and Member of Scientific Advisor Board
Dr. Jennifer A. Doudna Ph.D. (Age 60)
Founder & Member of Scientific Advisor Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NTLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings or view top-rated stocks.
What is Intellia Therapeutics' stock price target for 2024?: 13 brokerages have issued 12-month target prices for Intellia Therapeutics' stock. Their NTLA share price targets range from $29.00 to $107.00. On average, they expect the company's stock price to reach $67.00 in the next twelve months. This suggests a possible upside of 207.2% from the stock's current price.
View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts.
How have NTLA shares performed in 2024?: Intellia Therapeutics' stock was trading at $30.49 on January 1st, 2024. Since then, NTLA shares have decreased by 28.5% and is now trading at $21.81.
View the best growth stocks for 2024 here.
When is Intellia Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NTLA earnings forecast.
How were Intellia Therapeutics' earnings last quarter?: Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its earnings results on Thursday, February, 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.01. The business earned ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the company earned ($1.40) EPS.
What ETFs hold Intellia Therapeutics' stock?: ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Morningstar US Small Growth (MSGR), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), ARK Innovation ETF (ARKK), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX) and Franklin Genomic Advancements ETF (HELX).

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?: 12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Intellia Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).
When did Intellia Therapeutics IPO?: Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Intellia Therapeutics' major shareholders?: Intellia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and Green Alpha Advisors LLC (0.01%). Insiders that own company stock include David Lebwohl, Eliana Clark, Glenn Goddard, James Basta, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Laura Sepp-Lorenzino and Muna Bhanji.
View institutional ownership trends.
How do I buy shares of Intellia Therapeutics?: Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTLA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Intellia Therapeutics (NTLA) Stock Price, News & Analysis

Intellia Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Intellia Therapeutics Stock (NASDAQ:NTLA)

NTLA Stock Price History

NTLA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NTLA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™